Lease

Banco Itaú Chile Announces Termination of American Depositary Shares Program

Retrieved on: 
Thursday, November 9, 2023

SANTIAGO, Chile, Nov. 09, 2023 (GLOBE NEWSWIRE) -- BANCO ITAÚ CHILE (NYSE: ITCL; SSE: ITAUCL) (the “Company”) today announces that The Bank of New York Mellon, as depositary (the “Depositary”) issued, on November 8, 2023, a notice (the “Termination Notice”) to the holders of American Depositary Shares (the “ADSs”) representing common shares of the Company terminating the American Depository Receipt program (the “ADR Program”) according to the requirements under the Amended and Restated Deposit Agreement dated as of June 11, 2018 (the “Deposit Agreement”) among the Company, the Depositary, and owners and holders from time to time of ADSs issued thereunder.

Key Points: 
  • SANTIAGO, Chile, Nov. 09, 2023 (GLOBE NEWSWIRE) -- BANCO ITAÚ CHILE (NYSE: ITCL; SSE: ITAUCL) (the “Company”) today announces that The Bank of New York Mellon, as depositary (the “Depositary”) issued, on November 8, 2023, a notice (the “Termination Notice”) to the holders of American Depositary Shares (the “ADSs”) representing common shares of the Company terminating the American Depository Receipt program (the “ADR Program”) according to the requirements under the Amended and Restated Deposit Agreement dated as of June 11, 2018 (the “Deposit Agreement”) among the Company, the Depositary, and owners and holders from time to time of ADSs issued thereunder.
  • The ADR Program and the Deposit Agreement will be terminated on February 5, 2024 (the “Termination Date”).
  • The Termination Notice, a copy of which is included as an Annex to this press release, describes instructions to be followed by holders of ADSs in connection with the termination of the ADR Program and of the Deposit Agreement.

Global Biotechnology Collaboration Agreements Analysis Report 2023 with Directory of Deals Signed Since 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 13, 2023

The report on Collaboration Deals in Biotechnology offers a comprehensive analysis of why and how companies enter collaboration deals in the biotechnology sector.

Key Points: 
  • The report on Collaboration Deals in Biotechnology offers a comprehensive analysis of why and how companies enter collaboration deals in the biotechnology sector.
  • It covers collaboration deals from 2019 to 2023 and provides insights into the payment terms and other specifics of these deals.
  • The report includes a detailed listing of collaboration deals announced since 2019, recorded in the Current Agreements deals and alliances database.
  • Chapter 3 provides insights into the structure of collaboration deals, while chapter 4 reviews the leading collaboration deals since 2019, organized by headline value.

World Biotechnology Licensing Deals Analysis Report 2019-2023 with Directory of Deals by Company A-Z, Therapy Focus and Technology Type - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 13, 2023

The report on Licensing Deals in Biotechnology offers a comprehensive analysis of how and why companies engage in licensing deals within the biotechnology sector.

Key Points: 
  • The report on Licensing Deals in Biotechnology offers a comprehensive analysis of how and why companies engage in licensing deals within the biotechnology sector.
  • The report includes a detailed listing of licensing deals announced since 2019, recorded in the Current Agreements deals and alliances database.
  • Chapter 6 offers a comprehensive and detailed review of licensing deals organized by company A-Z, therapy, technology, and industry type.
  • Licensing Deals in Biotechnology provides the reader with the following key benefits:
    Directory of deals by company A-Z, therapy focus and technology type
    Licensing Deals in Biotechnology includes:
    Analyzing contract agreements allows due diligence of:
    What are the rights granted or optioned?

Global Diagnostics Distribution Deals Analysis Report and Directory 2016-2023 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 13, 2023

The "Distribution Deals in Diagnostics 2016 to 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Distribution Deals in Diagnostics 2016 to 2023" report has been added to ResearchAndMarkets.com's offering.
  • Fully revised and updated, the report provides details of distribution deals from 2016 to 2023.
  • Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals.
  • The deal directory includes a comprehensive listing of all distribution deals announced since 2016.

The Tide Turns for Renters as Asking Rents Post Biggest Decline in Over 3 Years

Retrieved on: 
Wednesday, December 13, 2023

This is a 0.6% decline in asking rents since October.

Key Points: 
  • This is a 0.6% decline in asking rents since October.
  • This jump in supply has left many landlords struggling to fill vacancies, motivating them to drop asking rents in some cases.
  • Better deals are easier to come by because landlords are doling out concessions and rents have started falling in a meaningful way.
  • Rising supply also means renters have more good options to choose from,” said Redfin Chief Economist Daryl Fairweather.

Restaurant Operating System, Otter, Releases Performance Data to Help Restaurants Understand Order Cancellation Trends and Mitigate Holiday Spike

Retrieved on: 
Tuesday, December 12, 2023

But maintaining operational excellence is equally critical in order to make the most of every order placed.

Key Points: 
  • But maintaining operational excellence is equally critical in order to make the most of every order placed.
  • In an era marked by a surge in online order volume, a critical strategy for upholding operational excellence involves minimizing order cancellations.
  • During this hour, the average restaurant’s cancellation rate is up to 4.8% higher than that of restaurants that do not close within the hour.
  • Out of the top 20 cuisine types, dessert restaurants are the most likely to experience order cancellations due to unavailable items.

NMHC, NAA Testify Before Congress on Housing Affordability Solutions

Retrieved on: 
Wednesday, December 6, 2023

The National Multifamily Housing Council (NMHC) and National Apartment Association (NAA) today testified before the House Financial Services Committee, Subcommittee on Housing and Insurance for their hearing titled “Housing Affordability: Governmental Barriers and Market-based Solutions.”

Key Points: 
  • The National Multifamily Housing Council (NMHC) and National Apartment Association (NAA) today testified before the House Financial Services Committee, Subcommittee on Housing and Insurance for their hearing titled “Housing Affordability: Governmental Barriers and Market-based Solutions.”
    Arianna Royster, president of Borger Residential, testified on behalf of the 100,000 combined members of NAA and NMHC to support sustainable policy solutions that improve housing affordability and protect the nation’s rental housing infrastructure for future generations of renters.
  • “To sustainably address the nation’s housing affordability challenge, policymakers should prioritize long-term solutions that will increase the supply of affordable rental housing.
  • Both solutions have been long supported by NAA and NMHC, and bipartisan and bicameral legislation to accomplish both of these have already been introduced in Congress this term.
  • It is clear that there is broad agreement between rental housing providers, renters and other housing stakeholders on what are effective solutions.

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, December 5, 2023

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on December 1, 2023 as inducements material to each employee entering into employment with KalVista.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on December 1, 2023 as inducements material to each employee entering into employment with KalVista.
  • The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $8.82 per share, which was equal to the closing price of KalVista common stock on the grant date.
  • Each stock option has a 10-year term and is subject to the terms and conditions of KalVista’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, December 4, 2023

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 52,000 shares of Astria’s common stock on December 1, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.

Key Points: 
  • Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 52,000 shares of Astria’s common stock on December 1, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.
  • The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.
  • The options were granted as an inducement material to two employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

Cool Company Ltd.: Granting Of Share Options And Restricted Stock Units To Primary Insiders and Mandatory Notification of Trades

Retrieved on: 
Friday, December 1, 2023

The Company anticipates that the shares underlying the vested RSUs will be issued to grantees on or after December 7, 2023.

Key Points: 
  • The Company anticipates that the shares underlying the vested RSUs will be issued to grantees on or after December 7, 2023.
  • Additionally, the Company’s board of directors (the “Board”) has resolved, in accordance with the LTIP, to authorize options (“Options”) and RSUs for 2023, as further detailed below.
  • Richard Tyrrell, CEO and Director of the Company, has on December 1, 2023 acquired 2,030 shares in the Company at a price of USD 12.49 per share.
  • The following Primary Insiders have been granted Options and RSUs, and purchased shares as per the below:
    Sami Iskander (Director) has been granted 37,123 Options.